TY  - CONF

T1  - Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

JO  - Ongoing Clinical Trials

PY  - 2015/05/01

AU  - Yardley DA

AU  - Coleman RE

AU  - Conte P

AU  - O'Shaughnessy J

AU  - Cortes J

AU  - Glück S

AU  - Brufsky A

AU  - Nabholtz J-MA

AU  - Li L

AU  - Miller J

AU  - Barton D et al

ED  - 

DO  - DOI: 10.1158/1538-7445.sabcs14-ot2-2-01

PB  - American Association for Cancer Research

Y2  - 2025/10/10

ER  -